New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer
European Urology Focus · 2024
DOI: 10.1016/j.euf.2024.07.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Urology Focus, 2024. Verfasst von Kévin Hébert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radioisotopes, Radiopharmaceuticals. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [177Lu]Lu-PSMA-617. Various molecules are currently being studied for TRT in prostate cancer. We review various combinations of isotopes and vectors being used to target prostate cancer cells and optimize pharmacokinetics. Promising innovations include chemical modifications to improve biodistribution, identification of new targets, and the use of novel radioisotopes such as α emitters. PATIENT SUMMARY: Our mini review summarizes research on targeted radioactive drugs for treatment of metastatic prostate cancer. Several promising radioactive pharmaceuticals are being evaluated in clinical trials, but more studies are necessary before these can be used in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Institut des Biomolécules Max Mousseron, University of Montpellier, Montpellier, France.
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; INSERM U1194, Institut de Recherche en Cancérologie de Montpellier, University of Montpellier, Mon…
Zitieren
APA
Hébert, K., Bodin-Cufi, P., Fersing, C., & Deshayes, E. (2024). New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer. European Urology Focus. https://doi.org/10.1016/j.euf.2024.07.016
Vancouver
Hébert K, Bodin-Cufi P, Fersing C, Deshayes E. New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer. European Urology Focus. 2024. doi:10.1016/j.euf.2024.07.016
BibTeX
@article{Hbert2024,
author = {Hébert, Kévin and Bodin-Cufi, Paul and Fersing, Cyril and Deshayes, Emmanuel},
title = {New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer},
journal = {European Urology Focus},
year = {2024},
doi = {10.1016/j.euf.2024.07.016}
}
EUVIMED